Bioventus (BVS) Competitors $6.40 -0.07 (-1.08%) Closing price 04:00 PM EasternExtended Trading$6.40 +0.00 (+0.08%) As of 05:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock BVS vs. EYE, LMAT, NVCR, SSII, ENOV, CNMD, CDRE, AORT, LQDA, and ESTAShould you be buying Bioventus stock or one of its competitors? The main competitors of Bioventus include National Vision (EYE), LeMaitre Vascular (LMAT), NovoCure (NVCR), SS Innovations International (SSII), Enovis (ENOV), CONMED (CNMD), Cadre (CDRE), Artivion (AORT), Liquidia Technologies (LQDA), and Establishment Labs (ESTA). These companies are all part of the "medical equipment" industry. Bioventus vs. Its Competitors National Vision LeMaitre Vascular NovoCure SS Innovations International Enovis CONMED Cadre Artivion Liquidia Technologies Establishment Labs National Vision (NASDAQ:EYE) and Bioventus (NYSE:BVS) are both medical equipment companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership. Which has more risk & volatility, EYE or BVS? National Vision has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. Comparatively, Bioventus has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Do insiders and institutionals hold more shares of EYE or BVS? 62.9% of Bioventus shares are held by institutional investors. 2.7% of National Vision shares are held by company insiders. Comparatively, 33.0% of Bioventus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is EYE or BVS more profitable? National Vision has a net margin of -1.40% compared to Bioventus' net margin of -7.11%. Bioventus' return on equity of 15.61% beat National Vision's return on equity.Company Net Margins Return on Equity Return on Assets National Vision-1.40% 3.44% 1.40% Bioventus -7.11%15.61%4.01% Which has better earnings and valuation, EYE or BVS? National Vision has higher revenue and earnings than Bioventus. National Vision is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNational Vision$1.82B1.10-$28.50M-$0.33-76.79Bioventus$567.70M0.93-$156.23M-$0.48-13.33 Do analysts prefer EYE or BVS? National Vision presently has a consensus target price of $23.00, suggesting a potential downside of 9.23%. Bioventus has a consensus target price of $13.75, suggesting a potential upside of 114.84%. Given Bioventus' stronger consensus rating and higher possible upside, analysts clearly believe Bioventus is more favorable than National Vision.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score National Vision 0 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.56Bioventus 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the media favor EYE or BVS? In the previous week, National Vision had 10 more articles in the media than Bioventus. MarketBeat recorded 11 mentions for National Vision and 1 mentions for Bioventus. Bioventus' average media sentiment score of 1.68 beat National Vision's score of 1.02 indicating that Bioventus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment National Vision 4 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Bioventus 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryNational Vision and Bioventus tied by winning 8 of the 16 factors compared between the two stocks. Get Bioventus News Delivered to You Automatically Sign up to receive the latest news and ratings for BVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BVS vs. The Competition Export to ExcelMetricBioventusSurgical & medical instruments IndustryMedical SectorNYSE ExchangeMarket Cap$525.72M$65.66M$5.70B$21.15BDividend YieldN/AN/A4.59%3.58%P/E Ratio-10.496.0527.9027.76Price / Sales0.93142.51442.1958.69Price / Cash12.5818.4136.5523.00Price / Book2.297.348.634.67Net Income-$156.23M-$25.32M$3.24B$993.85M7 Day Performance-1.39%1.79%3.22%1.16%1 Month Performance-5.33%6.08%10.72%4.99%1 Year Performance-14.21%56.17%34.94%12.54% Bioventus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BVSBioventus3.3714 of 5 stars$6.40-1.1%$13.75+114.8%-14.4%$525.72M$567.70M-10.491,200Positive NewsEYENational Vision2.8177 of 5 stars$25.31+0.9%$22.10-12.7%+91.6%$1.98B$1.82B-76.6913,411Positive NewsAnalyst ForecastLMATLeMaitre Vascular2.7232 of 5 stars$79.82+0.1%$97.83+22.6%-8.8%$1.80B$219.86M40.29490Analyst ForecastNVCRNovoCure3.7908 of 5 stars$16.10+0.5%$32.43+101.4%-12.0%$1.79B$605.22M-10.661,488News CoverageEarnings ReportSSIISS Innovations InternationalN/A$8.40+5.9%N/AN/A$1.54B$20.65M0.004Gap UpENOVEnovis2.9296 of 5 stars$26.35+0.2%$55.60+111.0%-39.8%$1.50B$2.11B8.377,367News CoverageHigh Trading VolumeCNMDCONMED4.7324 of 5 stars$47.78+0.3%$62.20+30.2%-31.5%$1.47B$1.31B12.573,900Upcoming EarningsCDRECadre3.3526 of 5 stars$32.27-1.1%$37.50+16.2%-12.3%$1.33B$567.56M34.362,284Positive NewsDividend AnnouncementAORTArtivion2.9247 of 5 stars$30.63+0.5%$32.40+5.8%+11.8%$1.30B$388.54M121.961,600News CoverageLQDALiquidia Technologies3.2872 of 5 stars$15.10+3.9%$26.89+78.1%+53.7%$1.24B$14M-9.5650News CoverageESTAEstablishment Labs2.0728 of 5 stars$42.60+2.5%$54.83+28.7%-10.1%$1.20B$166.02M-13.741,018Positive News Related Companies and Tools Related Companies National Vision Alternatives LeMaitre Vascular Alternatives NovoCure Alternatives SS Innovations International Alternatives Enovis Alternatives CONMED Alternatives Cadre Alternatives Artivion Alternatives Liquidia Technologies Alternatives Establishment Labs Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:BVS) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredTrump’s Endgame? (R.I.P. China)Tucked inside a Silicon Valley factory, a bold new tech is quietly emerging—one that could ignite a $12 trilli...Brownstone Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredBitcoin Beats Gold — But This Coin Could Beat Them BothBitcoin just hit a record high—but it’s not the top crypto play right now. Crypto analyst Juan Villaverde, ...Weiss Ratings | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioventus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioventus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.